Antiviral effects of simeprevir on multiple viruses

  • Antiviral Res. 2019 Dec;172:104607. doi: 10.1016/j.antiviral.2019.104607.
Zheng Li  1 ,  Fujia Yao  1 ,  Guang Xue  1 ,  Yongfen Xu  1 ,  Junling Niu  1 ,  Mengmeng Cui  1 ,  Hongbin Wang  1 ,  Shuxian Wu  1 ,  Ailing Lu  2 ,  Jin Zhong  1 ,  Guangxun Meng  3
Affiliations
  • 1. CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China; University of Chinese Academy of Sciences, Beijing, 100039, China.
  • 2. CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China; University of Chinese Academy of Sciences, Beijing, 100039, China; Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.
  • 3. CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China; University of Chinese Academy of Sciences, Beijing, 100039, China. Electronic address: [email protected].
PMID: 31563599 DOI: 10.1016/j.antiviral.2019.104607
Abstract

Simeprevir was developed as a small molecular drug targeting the NS3/4A protease of hepatitis C virus (HCV). Unexpectedly, our current work discovered that Simeprevir effectively promoted the transcription of IFN-β and ISG15, inhibited the Infection of host cells by multiple viruses including Zika virus (ZIKV), Enterovirus A71 (EV-A71), as well as herpes simplex virus type 1 (HSV-1). However, the inhibitory effects of Simeprevir on ZIKV, EV-A71 and HSV-1 were independent from IFN-β and ISG15. This study thus demonstrates that the application of Simeprevir can be extended to Other viruses besides HCV.

Keywords
EV-A71; HSV-1; IFN-β; ISG15; Simeprevir; ZIKV.
Products